PROCOMP

Post-LOE

prochlorperazine maleate

Jubilant Therapeutics

ANDAORALTABLET

Approved

Feb 1998

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

PROCOMP (prochlorperazine maleate) by Jubilant Therapeutics. Approved for schizophrenia. First approved in 1998.

Drug data last refreshed 3d ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications (1)

schizophrenia

Clinical Trials (1)

NCT06450899Phase 2Completed

Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

Started Aug 2024

57 enrolled

Acute Mountain Sickness

Company

Worked on PROCOMP at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.